Depreciation in USD of ELITE PHARMACEUTICALS INC /NV/ from 2013 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Depreciation history and change rate from 2013 to Q1 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Depreciation for the quarter ending 31 Mar 2025 was $364K, a 10.8% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ Depreciation for the twelve months ending 31 Mar 2025 was $1.23M, a 7.13% decline year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Depreciation for 2024 was $1.23M, a 7.13% decline from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Depreciation for 2023 was $1.32M, a 6.69% increase from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Depreciation for 2022 was $1.24M, a 3.58% increase from 2021.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $1.23M $364K +$35.5K +10.8% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 $1.19M $313K -$23.6K -7% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $1.21M $227K -$99.9K -30.5% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $1.31M $322K -$6.18K -1.88% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024
Q1 2024 $1.32M $328K +$14K +4.45% 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $1.31M $337K +$22K +6.99% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 $1.28M $327K +$11.2K +3.56% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $1.27M $328K +$35.5K +12.1% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $1.24M $314K +$17.1K +5.76% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $1.22M $315K +$21.6K +7.37% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 $1.2M $316K +$20.5K +6.94% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $1.18M $293K -$16.4K -5.31% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $1.19M $297K +$82.8K +38.6% 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $1.11M $293K -$213K -42.1% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 $1.33M $295K +$40.4K +15.8% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $1.28M $309K -$14.9K -4.6% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 $1.3M $214K -$109K -33.6% 01 Jan 2021 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $1.41M $506K +$179K +54.8% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q3 2020 $1.23M $255K -$73K -22.3% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 $1.3M $324K -$3.34K -1.02% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 $1.31M $323K +$11.6K +3.72% 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 $1.29M $327K +$9.29K +2.93% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021
Q3 2019 $1.28M $328K +$14.7K +4.71% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 $1.27M $327K +$27.2K +9.08% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 $1.24M $312K -$27.7K -8.16% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020
Q4 2018 $1.27M $318K +$85.3K +36.7% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 $1.19M $313K +$87.4K +38.6% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $1.1M $300K +$116K +62.6% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 $982K $339K +$144K +73.6% 01 Jan 2018 31 Mar 2018 10-K 21 Jun 2019
Q4 2017 $838K $232K +$65.8K +39.5% 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019
Q3 2017 $773K $226K +$60.2K +36.3% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 $712K $185K +$12.1K +7% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $700K $195K +$35.8K +22.4% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 $665K $167K -$7.31K -4.2% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018
Q3 2016 $672K $166K +$5.02K +3.12% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 $667K $173K +$14.6K +9.25% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 $652K $160K 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018
Q4 2015 $174K 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017
Q3 2015 $161K 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016
Q2 2015 $158K 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016

ELITE PHARMACEUTICALS INC /NV/ Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.23M -$94.1K -7.13% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 $1.32M +$82.7K +6.69% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 $1.24M +$42.8K +3.58% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 $1.19M -$105K -8.06% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023
2020 $1.3M -$5.95K -0.46% 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022
2019 $1.31M +$62.9K +5.06% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021
2018 $1.24M +$261K +26.5% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020
2017 $982K +$282K +40.2% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019
2016 $700K +$48.1K +7.37% 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018
2015 $652K +$86.3K +15.2% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018
2014 $566K $0 0% 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017
2013 $566K 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.